EOFlow, a provider of wearable drug delivery solutions, and Zihipp, a spin out from Imperial College London, agreed to sign a joint venture to focus on developing and delivering via wearable pump a family of gut-hormone analogues that promise rapid and dramatic weight loss without the common side effects seen with other such agents delivered via daily or weekly injection. Financial terms were not disclosed. "The adult obese population reaches 650 million worldwide. The obesity treatment market has huge unmet opportunities, and a powerful and rapid treatment for obesity can become a blockbuster product helping to address the global crisis in obesity. We at EOFlow are proud to be partnering with the world leaders in innovative weight loss research," Jesse J. Kim, EOFlow's founding CEO.